Safety and Efficacy Study of an A1-Adenosine Receptor Agonist to Slow Heart Rate in Atrial Fibrillation
Information source: Aderis Pharmaceuticals
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Atrial Fibrillation
Intervention: DTI-0009 (Drug)
Phase: Phase 2
Sponsored by: Aderis Pharmaceuticals
This study is designed to evaluate the safety of DTI-0009 in patients with atrial
fibrillation and to find the dose of DTI-0009 that lowers heart rates in patients with atrial
fibrillation with rapid ventricular response.
Study design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment
Minimum age: 18 Years.
Maximum age: 85 Years.
- Primary diagnosis of atrial fibrillation with rapid ventricular response of any
duration as documented by an ECG
- Presence of other significant cardiac disease or history of significant neurological,
hepatic,cardiovascular, renal, gastrointestinal, thyroid, respiratory, rheumatologic,
or hematologic disease or impairment that in the investigator’s judgment is serious
enough to preclude the patient from safely participating in the study
Locations and Contacts
Multiple locations, Richmond, Virginia, United States
Last updated: June 23, 2005